PMID- 17975012
OWN - NLM
STAT- MEDLINE
DCOM- 20080219
LR  - 20220410
IS  - 1521-0103 (Electronic)
IS  - 0022-3565 (Linking)
VI  - 324
IP  - 2
DP  - 2008 Feb
TI  - Alterations of glucose-dependent and -independent bladder smooth muscle 
      contraction in spontaneously hypertensive and hyperlipidemic rat.
PG  - 631-42
AB  - Alteration of bladder contractility was examined in the spontaneously 
      hypertensive and hyperlipidemic rat (SHHR; age, 9 months; systolic blood 
      pressure, >150 mm Hg; plasma cholesterol, >150 mg/dl). Carbachol (CCh) induced 
      time- and dose-dependent contractions in Sprague-Dawley (age-matched control) 
      rats and SHHR; however, maximal levels differed significantly (13.3 +/- 2.2 and 
      5.4 +/- 1.9 microN/mm(2) following 10 microM CCh treatment, respectively; n = 5). 
      This difference, which was maintained in calcium-replaced physiological salt 
      solution (PSS), was suppressed by pretreatment with rho kinase inhibitor, 1 
      microM Y27632 
      [(R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide]; moreover, 
      total activity of rho kinase was also reduced in SHHR bladder. Pretreatment of 
      bladders under high-glucose (HG) conditions (22.2 mM glucose-contained PSS for 30 
      min) led to enhancement of CCh-induced contraction solely in control animals. 
      Under HG conditions, both protein kinase C (PKC) activity and production of 
      diacylglycerol (DG) derived from incorporated glucose declined in SHHR bladder; 
      however, sustained elevation of plasma glucose level was not detected in SHHR. 
      These results suggested that bladder contractility dysfunction in SHHR is 
      attributable to alteration of rho kinase activity and the DG-PKC pathway. This 
      dysfunction may occur prior to chronic hyperglycemia onset in progressive 
      hypertension and hyperlipidemia.
FAU - Nobe, Koji
AU  - Nobe K
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Showa University, 
      1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan. 
      kojinobe@pharm.showa-u.ac.jp.
FAU - Yamazaki, Taigi
AU  - Yamazaki T
FAU - Kumai, Toshio
AU  - Kumai T
FAU - Okazaki, Masako
AU  - Okazaki M
FAU - Iwai, Shinichi
AU  - Iwai S
FAU - Hashimoto, Terumasa
AU  - Hashimoto T
FAU - Kobayashi, Shinichi
AU  - Kobayashi S
FAU - Oguchi, Katsuji
AU  - Oguchi K
FAU - Honda, Kazuo
AU  - Honda K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071101
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Glucose/*metabolism
MH  - Hyperlipidemias/*metabolism
MH  - Hypertension/*metabolism
MH  - In Vitro Techniques
MH  - Male
MH  - Muscle Contraction/*physiology
MH  - Muscle, Smooth/*metabolism
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Rats, Sprague-Dawley
MH  - Urinary Bladder/*metabolism
EDAT- 2007/11/03 09:00
MHDA- 2008/02/20 09:00
CRDT- 2007/11/03 09:00
PHST- 2007/11/03 09:00 [pubmed]
PHST- 2008/02/20 09:00 [medline]
PHST- 2007/11/03 09:00 [entrez]
AID - jpet.107.131334 [pii]
AID - 10.1124/jpet.107.131334 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2008 Feb;324(2):631-42. doi: 10.1124/jpet.107.131334. Epub 
      2007 Nov 1.